Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PHISOHEX is a topical emulsion small molecule approved in 1949 for dermatological use. The exact indication and mechanism of action are not specified in available data, but the formulation suggests a skin antiseptic or antimicrobial agent. As a legacy topical product, it represents a mature portfolio asset for Sanofi.
As LOE approaches, the brand team is likely consolidating and shifting focus toward generic transition or discontinuation planning; expect smaller, defensive teams rather than growth-oriented roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PHISOHEX offers minimal career growth opportunity given its LOE approaching status and zero linked job count. Roles on this product focus on legacy management, regulatory compliance, and managed decline rather than innovation or commercial expansion.
Worked on PHISOHEX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.